Description
Adcetris (Brentuximab)50mg Online
Adcetris (brentuximab vedotin) is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Adcetris is indicated for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates and the treatment of patients with systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen.
Adcetris is used to treat classical Hodgkin lymphoma that could relapse or has already relapsed after a stem cell transplant or treatment with other cancer medications. Adcetris is also used to treat anaplastic large cell lymphoma that affects organs throughout the body (systemic) or that is confined only to the skin (primary cutaneous). It is usually given for these conditions after other treatments have failed.
Adcetris was approved for anaplastic large cell lymphoma by the US Food and Drug Administration (FDA) on an “accelerated” basis. In clinical studies, brentuximab vedotin produced complete or partial remission in many people. However, further studies are needed to determine if this medicine can lengthen survival time. Previously untreated Stage 3 or 4 cHL: Adult patients with newly diagnosed Stage 3 or 4 classical Hodgkin lymphoma (cHL) in combination with chemotherapy (adriamycin, vinblastine, and dacarbazine)
Consolidation therapy in cHL: Adult patients with cHL at high risk of coming back or becoming worse after a stem cell transplant (SCT)
Relapsed cHL: Adult patients with cHL after an SCT fails or after at least 2 combination chemotherapy treatments fail and SCT is not an option.
Untreated sALCL or other CD30-expressing PTCL: Adult patients with newly diagnosed systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified, in combination with chemotherapy (cyclophosphamide, doxorubicin,
and prednisone).
Relapsed sALCL: Adult patients with sALCL after at least 1 combination chemotherapy treatment fails.
Relapsed pcALCL or CD30-expressing MF: Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy (treatment that reaches and affects the entire body).
